samedan logo

 
 
spacer
home > ict > summer 2007 > building consensus
PUBLICATIONS
International Clinical Trials

Building Consensus

Henry Yau at the Clinical Trials Centre, Hong Kong, rethinks the clinical trial agreement management process

Management of clinical trial agreements/contracts (CTAs) for industry-sponsored clinical trials between sponsors and study sites has been deemed a major rate-determining step for the initiation of clinical trials. Study sites are commonly blamed by the industry for their unfamiliarity with legal parlance, incomplete knowledge of legal and regulatory requirements and requests for specific arrangements that deviate from sponsors’ standard contract terms and conditions.

Sponsors, on the other hand, are condemned by study sites for using tricky and difficult-to-understand legal jargon that is biased towards sponsors and unfair to study sites. Within a sponsor's organisation, project teams frequently accuse their legal departments of wasting time on debating meaningless legalese. Legal counsels used to complain to project teams about their overlooking potential legal risks. Such conflicting views among different parties has resulted in fewer industry players attempting to look into the issue from a broader perspective and propose holistic solutions – hence the problem persists.

CTA MANAGEMENT PROCESS

Contracts are normally seen as specifically legal documents. Drafting, negotiating and managing CTAs are, therefore, commonly regarded by many sponsors, contract research organisations (CROs) and study sites as purely legal matters and the sole responsibility of legal counsels. This, however, reflects the incomplete understanding of the functions of contracts. Whilst contracts are intended to be legally binding, the primary purpose of any contract is not to take the contract parties to court, but to set out the rights and responsibilities of those parties and, ultimately, to facilitate the accomplishment of the goals of the parties under the contract. Management of CTAs is a multi-disciplinary process involving four interlocking components (see Figure 1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Henry Yau has a BSc in Biochemistry and a MBA in Finance. He has 14 years’ experience in the pharmaceutical and petrochemical industries. He started his career in the pharmaceutical industry with a marketing and regulatory position in Rhone-Poulenc, and subsequently assumed a business development position in a petrochemical group. Since 2000, Henry has worked at the Clinical Trials Centre of The University of Hong Kong. Henry is currently the Assistant Director and Business Development Manager of the Clinical Trials Centre, Hong Kong, and is principally responsible for managing its strategic business development functions.
spacer
Henry Yau
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

21-22 April 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement